Neil Johnson

Title: Neil Johnson: Innovator in KRAS Modulation

Introduction

Neil Johnson is a prominent inventor based in Downingtown, PA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate KRAS mutations. With a total of two patents to his name, Johnson's work is paving the way for advancements in cancer treatment.

Latest Patents

Johnson's latest patents include "Pyrimidine based modulators and uses thereof" and "KRAS modulators and uses thereof." The first patent provides compounds that are useful for modulating KRAS GD12 and/or other G12 mutants. The second patent details KRAS modulating compounds that are effective for the same purpose, showcasing his focus on addressing critical mutations in cancer biology.

Career Highlights

Currently, Johnson is associated with Quanta Therapeutics, Inc., where he continues to innovate in the field of cancer therapeutics. His work is characterized by a commitment to developing effective treatments that target specific genetic mutations, which are crucial in the fight against cancer.

Collaborations

Some of his notable coworkers include Hong Lin and Juan Luengo, who contribute to the collaborative environment at Quanta Therapeutics, Inc. Their combined expertise enhances the research and development efforts within the company.

Conclusion

Neil Johnson's contributions to the field of KRAS modulation are significant, and his ongoing work at Quanta Therapeutics, Inc. holds promise for future advancements in cancer treatment. His innovative spirit and dedication to research continue to inspire progress in the pharmaceutical industry.